Objective-To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO) to enable comparative effectiveness treatment studies.
INTRODUCTION
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that mainly affects children and adolescents. Clinical presentations range from mild and sometimes limited unifocal disease to severe, chronically active or recurrent inflammation of multiple bones. The latter is referred to as chronic recurrent multifocal osteomyelitis (CRMO). Here we will use the term "CNO" to refer to the entire spectrum of this disease. CNO can be complicated by vertebral compression fractures, kyphosis, and leg length discrepancy when it is not recognized early or treated adequately. The diagnosis of CNO is made by excluding alternatives in the differential diagnosis including malignancy (leukemia, lymphoma, and primary or metastatic bone tumors), Langerhans cell histiocytosis, and infection. Clinical assessment in conjunction with serum inflammatory parameters and imaging studies, particularly magnetic resonance imaging (MRI), are crucial for the diagnosis and monitoring of disease activity of CNO (1) .
Because of significant variation in clinical treatment practices among pediatric rheumatologists, standardized treatment regimens (consensus treatment plans, CTPs) have been developed within the Childhood Arthritis and Rheumatology Research Alliance (CARRA), a North American organization comprised of pediatric rheumatologists and researchers, for systemic juvenile idiopathic arthritis (JIA) (2) , polyarticular JIA (3), lupus nephritis (4), juvenile localized scleroderma (5) , and juvenile dermatomyositis (6) . These CTPs enable progress to be made towards identifying optimal treatment for these diseases through prospective observational studies. The developed CTPs were based on best available evidence and current treatment practices, and generated through consensus methodology including nominal group techniques. The intention of these CTPs was to limit treatment practice variation to enable researchers to conduct comparative effectiveness studies. Because of the variability in second line treatment of CNO, we have worked to develop standardized treatment plans and data collection forms and measures for CNO patients with an NSAID-refractory course and/or with active spinal lesions. These CTPs will facilitate future comparative effectiveness studies for CNO. It must be noted that CTPs are not meant to be clinical care guidelines. A treating physician may deviate from the CTP at any time if it is deemed appropriate for the patient's care.
MATERIALS AND METHODS
The CARRA CNO work group of the CARRA Scleroderma, Vasculitis, Autoinflammatory and Rare Diseases (SVARD) subcommittee consists of board-certified pediatric rheumatologists with special interest and expertise in CNO and family representatives. The CARRA CNO work group reviewed evidence published between 1966 and April 29, 2015. A literature search was conducted using Pubmed with the following MESH terms: SAPHO[All Fields] OR (Chronic[All Fields] AND nonbacterial[All Fields] AND ("osteomyelitis"[MeSH Terms] OR "osteomyelitis"[All Fields])) OR ("Chronic recurrent multifocal osteomyelitis"[Supplementary Concept] OR "Chronic recurrent multifocal osteomyelitis"[All Fields] OR "chronic recurrent multifocal osteomyelitis"[All Fields]) OR (noninfectious[All Fields] AND ("osteomyelitis"[MeSH Terms] OR "osteomyelitis"[All Fields])) AND (hasabstract[text] AND "humans"[MeSH Terms] AND English[lang]). In total, 398 articles were screened. A complete list of literature is included in Supplement 1.
There was no randomized controlled study or case-control study in CNO. Therefore, case series, historical cohort, and prospective observational studies with at least 3 months of follow-up data in the pediatric population were included for review. Twenty-one articles met the criteria. Eleven additional articles published between April 29, 2015 and January 1, 2017 were later included. The group formulated clinical scenarios, analyzed survey responses from CNO workgroup members, organized consensus meetings, and finalized treatment plans. Levels evidence were graded from 2 to 5 according to guidelines established by the Oxford Centre for Evidence-Based Medicine (CEBM; online at www.cebm.net).
Planning meetings
Members of the CARRA CNO work group initiated the process to develop CTPs at the CARRA 2014 annual conference. Monthly conference calls within the work group were then used to develop a survey to CARRA members and ongoing discussion of the CTPs. The targeted population included patients refractory to NSAID monotherapy and/or with active spinal lesions because physicians perceived less favorable outcomes and need of additional treatment in such patients. At the planning meeting (Austin, TX, April 2015), a survey was sent to the SVARD subcommittee to collect responses of diagnostic, disease monitoring, and therapeutic approaches chosen by CARRA-affiliated pediatric rheumatologists. Further discussion at that meeting outlined the core substance of the planned CTPs. A detailed survey was sent to the CNO group (67% of 34 members responded) asking for comments on summarized plans and proposed options (see Supplement 2) . At the American College of Rheumatology annual conference (San Francisco, CA, 2015), a second meeting was attended by 13 pediatric rheumatologists. Patient characteristics, treatment options, and imaging monitoring were discussed in depth.
Consensus meetings
At the CARRA annual conference (Toronto, 2016), a CNO meeting was attended by 6 family representatives and 30 pediatric rheumatologists, one of whom acted as the facilitator (YZ). The facilitator and family representatives participated in the discussion but were not eligible to vote.
Nominal group technique was used to achieve consensus (defined as ≥80% agreement within the group) on all questions considered during the meeting and subsequent conference calls. The facilitator framed the question to be discussed and presented data from the survey relevant to each question. Potential responses to the question were shown based on prior group discussion. Each participant had the opportunity to express his or her opinion for 1-2 minutes without interruption. Potential responses were updated accordingly.
Participants were then given the opportunity to vote for their preferred responses to the questions using a show-of-hand vote. Eighty percent or more of positive or negative votes was considered a consensus vote. If consensus was not achieved, participants were given the opportunity to speak uninterrupted for 1-2 minutes to share their thought process. After excluding answers that would not result in consensus votes, or after modifying potential responses, another vote was taken. If necessary, this process continued for two rounds on each question. If a clear consensus was not reached after two rounds, the decision was made to move to the next question.
RESULTS

What standardized disease-assessment tools of CNO have been reported?
Literature review of the clinical cohort studies on CRMO, CNO and pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome revealed a lack of agreement on a standardized evaluation tool. Two articles have reported standardized assessments with level IV evidence. Beck and colleagues used a PedCNO score (7) to assess prospectively the responses to naproxen in 37 children with CNO. After 12 months of treatment, 54% of patients achieved PedCNO 70 (at least 70% improvement in at least 3 out of 5 core variables and no more than one of remaining variables deteriorating by more than 70%). Within the core set, erythrocyte sedimentation rate (ESR), and the childhood health assessment questionnaire (CHAQ) had a floor effect by 3 months whereas the number of radiological lesions by MRI, severity of disease estimated by the physician, and severity of disease estimated by the patient or parent continued to improve over 12 months. Zhao and colleagues further described the characteristics of CNO lesions based on MRI findings using a grading system to score the severity of bone edema and soft tissue inflammation as well as the presence of periosteal reaction, hyperostosis, growth plate damage and vertebral compression (8) . Applying this scoring tool to two retrospective cohorts of patients with CNO, authors found a significant decrease of number of nonvertebral lesions and maximum severity of bone edema in the group receiving aggressive treatment.
What evidence of effectiveness of second-line treatments is there in CNO?
Studies focusing on children with CNO who failed NSAID treatment are limited. Seven articles have reported treatment of pamidronate in CNO with level IV evidence. Kerrison and colleagues reported significant pain relief and improved activity and well-being with pamidronate use in seven children (three with spinal lesions) who failed NSAIDs (9). Simm et al. with four cycles of pamidronate at 1 mg/kg/day on three consecutive days every three months (14) . Two patients exhibited a good response, six individuals showed a moderate response, one had a mild response, while two failed to respond based on repeated whole body MRIs. Schnabel et al. described pamidronate to be highly effective in CNO patients refractory to standard treatment with NSAIDs and/or glucocorticoids (15) .
Published data on the use of tumor necrosis factor (TNF)-alpha inhibitors (TNFi) in CNO are more limited. (20) . On the other hand, etanercept was effective in all five patients in a small childhood series (21) . Antiinterleukin (IL)-1 has been reported in fewer pediatric cases (20) . In an adult cohort (n=6), anakinra improved the patient global assessment of disease activity within one month in five patients (22) . Currently, there is no consensus on subsequent treatment for patients refractory to NSAID treatment. Based on a survey sent to members of CARRA, 95% of treating physicians responded (41% response rate) use NSAIDs as first-line treatment in children with a new diagnosis of CNO (evidence level V) (24) . For patients who failed NSAID treatment, the most commonly used treatments were reported as methotrexate (67%), TNFi (65%), and bisphosphonates (46%) (24) . These results guided the development of consensus treatment plans (CTPs).
What patient characteristics should be included for this CTP?
Initial intent was to include all children with CNO. However, through further work group discussion, it was agreed that NSAIDs were generally considered first-line treatment for all newly diagnosed patients without active spinal lesions. Therefore, our attention turned to a more defined subset: patients refractory to NSAIDs and/or with active spinal lesions. The definition of "refractory to NSAID" was debated among group members, and the duration of initial NSAID trial was decided to be a minimum of 4 weeks. Based on the physician's discretion and disease severity, further treatment may be initiated. The rationale of including active spinal lesions as a patient characteristic is the perceived significance of increased risk of vertebral fracture (11) (12) (13) . The age limit for the CTP was set to 21 years, because children and adults younger than 21 years of age are commonly seen and followed in children's hospitals. Patients with malignancy, infectious osteomyelitis, or other contraindications to the proposed treatment agents are not eligible for the CTP. Detailed characteristics of patients are provided in Table 1 .
What standardized data should be collected at the initial evaluation?
Each patient should undergo a complete clinical assessment, including comprehensive musculoskeletal exam, since clinically active lesions are defined by findings of focal tenderness, and/or swelling, and/or warmth in addition to patient's report of pain. Active joint counts with arthritis and enthesitis are important to record because of reported overlap between enthesitis-related arthritis (ERA) and CNO. Due to the lack of validated CNOspecific patient reported outcomes, both CHAQ and Patient-Reported Outcomes Measurement Information System (PROMIS) will be collected. Based on previously published diagnostic criteria of CNO (19, 25) and results from physician surveys (24), a bone biopsy was recommended unless typical lesions including the clavicle or symmetrical lesions at metaphysis/epiphysis of long bones or comorbidities such as inflammatory bowel disease, palmoplantar pustulosis, or psoriasis are present. All participants agreed that whole body imaging is required to identify all bone lesions. Whole body MRI is preferred (26) . A suggested protocol is included in Table 1 . Bone scintigraphy was considered an adequate alternative if whole body MRI is not available. Total number of bone lesions is recorded per radiologist's report. A baseline MRI (whole body or regional) is required to define active bone lesions based on the presence of bone marrow edema from short tau inversion recovery (STIR) or T2 fat saturation sequences, as the MRI findings are important to guide treatment decisions and to monitor disease activity (8, 11, 13, 24, 27) . The normal range of bone marrow signal on MRI has not been established yet. Therefore, distinguishing abnormal marrow signal is subject to the experience of the radiologist reading the image. The size and severity of bone edema and/or soft tissue inflammation is determined by the radiologist based on previous description (8) . Bony expansion, growth plate damage, and vertebral compression were considered disease damage and not active inflammation (8) . In children who were treated with bisphosphonates, a linear hyperintense signal should not be mistaken as active lesions. Laboratory data including complete blood cell counts, ESR, and CRP are required for disease monitoring. Alkaline phosphatase at baseline is required to screen for metabolic bone disease. HLA-B27 has been reported with association of cutaneous diseases in CNO and strong association with ERA. Thus, participants agreed to include HLA-B27 test.
What are the most important therapies to include?
We reviewed the literature for medications with reported efficacy in CNO refractory to NSAIDs, including non-biological disease modifying anti-rheumatic drugs (DMARDs), TNFi, and bisphosphonates (8) (9) (10) (11) (12) (13) (14) 17, 18, 20, 28, 29) . There are no head-to-head comparisons among these treatments, even though current data suggested higher remission rates in children treated with TNFi than those with DMARDs (17, 18) . Among physicians in CARRA, methotrexate, TNFi, and bisphosphonates were most commonly used after children with CNO failed NSAIDs (24) . Consensus was reached to include the three most commonly applied combinations of medications in final CTPs. There was a discussion on whether concomitant NSAIDs and/or oral glucocorticoid "bursts" were allowed. The group decided on the optional use of both with limits on the allowable duration of glucocorticoids due to their known side effects. Glucocorticoid "bursts" were defined as glucocorticoids (equivalent dosing of prednisone) up to 2 mg/kg/day (maximum daily dose of 60 mg) for up to a total of 6 weeks of treatment with or without tapering. Chosen strategies were in agreement with current practice echoed by participants. In patients treated with TNFi, concomitant methotrexate was allowed to suppress formation of human anti-chimeric anti-TNF antibody production (particularly with infliximab) as well as for combination therapy ( Table 2) .
What dose/route/frequency should be used for each medication in the CTPs?
The most commonly used DMARD by physician members in the CARRA survey was methotrexate (34%) (24) . However, within the CNO group, members reported that sulfasalazine was commonly used based on personal experiences. Thus, only these two DMARDs were included in the protocol. TNFi reported for use in CNO were limited to etanercept, adalimumab, and infliximab. The frequency of using these TNFi among surveyed CARRA physician members was 26% with adalimumab and infliximab, and 17% with etanercept (24) . Thus, all 3 were included in the protocol. Other TNFi may be used by the treating physician with discretion. Mandatory tuberculosis screening is required prior to the initiation of a TNFi. The dosing of DMARDs and TNFi followed standard JIA treatment regimens as reported in the literature and clinical practice ( Table 2) . Pamidronate was the most commonly reported bisphosphonate (9-15) whereas zolendronic acid was only reported as concomitant treatment in a single study (8) . However, both were used by physicians within CARRA (pamidronate 79%, zolendronic acid 21%) (24) . Therefore, in the bisphosphonate arm, pamidronate and zolendronic acid were both included in the protocol. The dosing of bisphosphonates was based on the pediatric endocrinology literature and has been utilized in case series of CNO and SAPHO patients ( Table 2 ). Suggested toxicity monitoring and immunizations are included in Appendix 1.
What criteria should be used to determine treatment failure?
Various parameters have been used to define "treatment response" in CNO, including the PedCNO score (7) , total number of clinically active bone lesions, and severity of bone edema and soft tissue inflammation on MRI (8) . After discussion, group consensus was reached to use a composite score similar to the JIA core set based on significant variation of symptoms and a high incidence of pain amplification (pain in the absence of inflammatory activity) among CNO patients. Various items were proposed by group members and after indepth discussion; the group identified the top 6 individual items. These treatment response criteria are considered as expert opinion (evidence level IV). Thereby, a modified composite score was proposed by replacing CHAQ and severity of disease estimated by patient or parent with the size and severity of bone marrow edema and/or soft tissue inflammation in the MRI and the total count of clinically active lesions. These criteria have not been validated and are merely suggestions for physicians to consider during their clinical management of children with CNO. As shown in Table 3 
At what intervals should patients be followed for the purposes of data collection?
Consensus was reached to follow intended CNO patients a minimum of every 3 months for the first year. The follow-up visit may occur earlier if the physician has concerns about the clinical course and/or treatment response. In addition to routine history, physical exams and laboratories, MRI is strongly recommended to objectively assess disease activity at 6 and 12 months after adjusting therapy. Additional imaging is recommended in suspected disease flares or persistent activity despite treatment escalation. Whole body MRI is generally preferred, but regional MRI of known sites is acceptable in unifocal disease or if whole body MRI is not available.
What data should be collected at follow-up?
Consensus was reached to minimize data collection for practicability using a standardized form. Table 4 includes clinical parameters, imaging and laboratory tests considered essential for CNO follow-up assessment. 
DISCUSSION
To our knowledge, these are the first consensus treatment plans developed for children with CNO by members of a professional society. Our work demonstrates the feasibility of achieving consensus in treatment plans and data collection for a rare and under-studied pediatric rheumatic disease using a combination of surveys, a comprehensive literature search, and nominal group technique.
Lack of validated criteria for classification and follow-up, as well as standardized treatment, has hindered the progress of comparative effectiveness research in CNO. Current approaches are solely based on small case series, personal experience, and expert opinion (1) . Our work is one step forward towards standardizing applied treatment regimens based on existing data and collection of a minimal set of data. This may allow objective evaluation of the effectiveness of different treatments. In addition, consistent imaging data collection will provide important corroboration with patient reported outcomes and the physician's clinical assessment.
The CTPs presented here reflect current clinical practice of CARRA members. Thus, they are highly applicable and more likely to be adopted in daily practice by practitioners. The intent of these CTPs is to reduce the variation of applied treatment options so that meaningful data from as many patients as possible can be collected in an observational study.
Of note, the proposed treatment plans are standardized regimens without strong evidence of which treatment is optimal. They are not to be misinterpreted as guidelines as their intention is to enable further study to identify optimal treatment. These CTPs currently do not include any biologic treatments other than TNFi, because of the rarity of their use in CNO and a lack of support by the available literature. However, these CTPs may be revised in the future to include other potentially effective forms of treatment as more evidence becomes available.
Bone biopsy was not required for all children with CNO (18, 25) . However, other diagnoses must be excluded prior to using these plans based on the treating physician's thorough evaluation. These plans should only be used when physicians are confident of the diagnosis.
Since whole body MRI offers the most thorough imaging evaluation for CNO without exposure to radiation, it should be considered the gold standard. However, regional MRIs (or a series of multiple regional MRIs) are considered reasonable when whole body MRI is not available. Other whole body imaging, such as bone scintigraphy, is considered an alternative one-time baseline assessment whenever whole body MRI is not available.
The CTP presented here has limitations. First, this CTP does not extend beyond 12 months of treatment. Second, this CTP does not include biologic treatments other than TNFi. Third, validated disease monitoring scoring tools are lacking and the proposed criteria of treatment failure need further evaluation and validation.
CONCLUSION
Three standardized consensus treatment plans were developed for patients with CNO with insufficient response to NSAIDs and/or the presence of active spinal lesions. Use of these treatment plans will provide the opportunity to generate meaningful data for future prospective observational studies to evaluate their effectiveness in children with CNO.
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Toxicity monitoring
• Check CBC with differential, serum creatinine, and liver enzymes prior to initiation and every 6 months during chronic daily use (8 
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Author Manuscript Table 2 Consensus treatment plans for the first 6-12 months Table 3 Criteria for treatment failure at 3 months (when a patient fails to improve on at least 4/6 of the criteria or over 50% of applicable criteria) & Clinically active lesion is defined as a body part with focal tenderness, and/or swelling, and/or warmth in addition to patient's report of pain at a known CNO lesion site.
Summary of protocols
* Abnormal ESR is defined as ≥20 mm/hr and abnormal CRP is defined as ≥1 mg/dL.
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